Trial Profile
The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four-arm, parallel, placebo-controlled and active descriptive-comparator, 40 week trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Plovamer (Primary) ; Glatiramer acetate
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 16 Aug 2023 This trial has been completed in Czechia
- 13 Jun 2011 New trial record